Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

Background Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking.Patients and methods We performed an international, multicenter observational study to confirm safet...

Full description

Saved in:
Bibliographic Details
Main Authors: Dominik Bettinger, Bo Yu, David Szafron, Yinghong Wang, Mahvish Muzaffar, Thomas Marron, Uqba Khan, Yi-Hsiang Huang, David J Pinato, Ahmed Kaseb, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Musharraf Navaid, ChiehJu Lee, Anushi Bulumulle, Sonal Paul, Petros Fessas, Neil Nimkar, Hannah Hildebrand, Tiziana Pressiani, Yehia I Abugabal, Nicola Personeni, Lorenza Rimassa, Celina Ang, Abdul Rafeh Naqash, Francesca Benevento
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001033.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/8/2/e001033.full

Similar Items